
|Videos|January 12, 2023
The Advent of Systemic Therapy for HCC
Drs Singal and Lewandowski review use of tyrosine kinase inhibitors, sorafenib and lenvatinib, and discuss trials that combined systemic therapy with chemoembolization.
Advertisement
Episodes in this series

Advertisement
Related to this article

Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC
2
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
3
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
4
TCR-Based Strategies and Tolerable Combinations Begin to Narrow the Outcome Gap in Uveal Melanoma
5

